Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 MARIPOSA ...

(RTTNews) - Johnson & Johnson (JNJ) Thursday reported positive data from the Phase 3 MARIPOSA study evaluating rybrevant plus lazcluze versus osimertinib in the first-line treatment of patients ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

But that status has recently come under attack from Johnson & Johnson’s combination of Rybrevant and Lazcluze. Rybrevant, an EGFRxMET bispecific antibody, is also approved in combination with ...

Pfizer and Arvinas have shared promising top-line results from a late-stage study of their investigational protein degrader vepdegestrant in a subset of breast cancer patients. The phase 3 VERITAC-2 ...

As always: “Other teams are just teams. They’re smarter than you, they’re luckier than you and whatever you think is going to happen, the exact reverse opposite is going to happen.” They ...

MLB, Topps and Nike have partnered to recognize baseball's elite performers from last season with custom gold-embellished MLB logos on their jerseys that will then be used to create trading cards.

Northvolt AB today announced that it has filed for bankruptcy in Sweden. It says Northvolt North America is solvent, but what will happen to its massive EV battery plant project in Canada?

Embracing a "one day at a time" approach enhances appreciation for life's daily moments and opportunities for gratitude. Cancer experience fosters a deeper respect for health, leading to improved diet ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ulcerative colitis successfully met all primary endpoints. Johnson & Johnson’s ...

The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics,” is a game-changer for biopharmaceutical ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer. At the 42nd Annual Miami Breast Cancer Conference, Dr. Sara M. Tolaney sat down for ...